Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostate Cancer Metastatic × rucaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 5 Ovarian Neoplasms 4 Fallopian Tube Neoplasms 4 Endometrial Neoplasms 4 Uterine Cervical Neoplasms 2 Prostatic Neoplasms 2 Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Prostate Cancer Metastatic 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Metastatic Castration-resistant Prostate Cancer 1 Mesothelioma, Malignant 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Adenocarcinoma of the Oesophagus 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1 ATM Gene Mutation 1

Interventions

Radiosurgery 5 Androgen Antagonists 4 enzalutamide 2 Prednisone 2 Docetaxel 2 talazoparib 1 sipuleucel-T 1 rucaparib 1 olaparib 1 gallium 68 PSMA-11 1 darolutamide 1 cabazitaxel 1 apalutamide 1 XRP6258 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 Hematologic Tests 1 Granulocyte Colony-Stimulating Factor 1 Gonadotropin-Releasing Hormone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03413995 2024-10-16

TRIUMPH

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed

12 enrolled 11 charts

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡